| Date | Title | Description |
| 31.10.2024 | I-Mab: Pioneering the Future of Cancer Immunotherapy | In the bustling world of biotechnology, I-Mab stands out like a lighthouse in a storm. This U.S.-based company is dedicated to developing innovative immunotherapies for cancer treatment. With a focus on highly differentiated therapies, I-Ma... |
| 31.10.2024 | I-Mab to Release Q3 2024 Financial Results on November 14, 2024 | ROCKVILLE, Md., Oct. 31, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a US-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, t... |
| 30.10.2024 | I-Mab to Present Givastomig Phase 1 Optimal Dose Estimation Data at SITC 2024 | - Poster to be presented in a late-breaking abstract session at the Society for Immunotherapy of Cancer (SITC) on Saturday, November 9, 2024
ROCKVILLE, Md., Oct. 30, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S... |
| 28.10.2024 | I-Mab to Participate at the Truist Securities BioPharma Symposium | ROCKVILLE, Md., Oct. 28, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a US-based, global, biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that manag... |
| 10.09.2024 | I-Mab Presents Positive Uliledlimab Pharmacokinetics Data at 2024 World Conference on Lung Cancer | - Pharmacokinetic/pharmacodynamic (PK/PD) modeling data from three Phase 1 studies providing dosing support for upcoming clinical trials
- Exposure-Response (E-R) Analysis showed a positive correlation between uliledlimab concentration and ... |
| 29.08.2024 | I-Mab: Navigating the Waters of Biotech with Strategic Precision | I-Mab, a clinical-stage biotech company based in Rockville, Maryland, is making waves in the cancer treatment landscape. With a laser focus on immunotherapies, the company is charting a course through turbulent waters, driven by innovation ... |
| 28.08.2024 | I-Mab Reports 1H 2024 Financial Results, Pipeline Progress, and Business Updates | Completed divestiture of China operations
Uliledlimab IND clearance paves the way for U.S. combination studies in first-line mNSCLC (CD73 antibody)
Clinical collaboration and supply agreement with Bristol Myers Squibb strengthens givastomig... |
| 26.08.2024 | I-Mab to Participate at the H.C. Wainwright 26th Annual Global Investment Conference | ROCKVILLE, Md., Aug. 26, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a US-based, global, clinical-stage biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today annou... |
| 07.08.2024 | I-Mab Appoints U.S. Auditor, PricewaterhouseCoopers LLP (PwC) | Engagement is part of I-Mab's commitment to transition to a U.S.-based biotech
PwC to serve as independent registered public accounting firm for FY 2024
ROCKVILLE, Md., Aug. 7, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) ("I-Mab", t... |
| 15.07.2024 | I-Mab Announces Leadership Transitions | ROCKVILLE, Md., July 15, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company" or "I-Mab"), a U.S.-based, global biotech company, announced today that the Board of Directors of the Company has appointed Mr. Wei Fu as ... |
| 15.07.2024 | I-Mab Announces Leadership Transitions | ROCKVILLE, Md., July 15, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company" or "I-Mab"), a U.S.-based, global biotech company, announced today that the Board of Directors of the Company has appointed Mr. Wei Fu as ... |
| 06.06.2024 | I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer | ROCKVILLE, Md., June 6, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapi... |
| 05.06.2024 | I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers | I-Mab enters clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer.
Collaboration b... |
| 22.05.2024 | I-Mab to Participate at the Jefferies Global Healthcare Conference | ROCKVILLE, Md., May 22, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a U.S.-based global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of can... |
| 30.04.2024 | I-MAB Filed 2023 Annual Report on Form 20-F | ROCKVILLE, Md., April 30, 2024 /PRNewswire/ -- I-Mab (the "Company") (NASDAQ: IMAB), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunothera... |
| 30.04.2024 | I-MAB Filed 2023 Annual Report on Form 20-F | ROCKVILLE, Md., April 30, 2024 /PRNewswire/ -- I-Mab (the "Company") (NASDAQ: IMAB), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunothera... |
| 05.04.2024 | I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference | ROCKVILLE, Md., April 5, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of c... |
| 03.04.2024 | I-Mab Announces Closing of the Divestiture of Business Operations in China | ROCKVILLE, Md., April 3, 2024 /PRNewswire/ -- I-Mab (the "Company") (NASDAQ: IMAB) a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapi... |
| 15.03.2024 | I-Mab Reports Full Year 2023 Financial Results and Business Update | Recently announced agreement to divest assets and business operations in China marks an important milestone for the Company; the transaction is expected to close by the end of March 2024
Uliledlimab (CD73 antibody) on track to file an IND i... |
| 07.02.2024 | I-Mab Signs Agreement to Divest its Assets and Business Operations in China | Agreement marks an important milestone to advance the Company's intent to become a U.S.-based biotech
Agreement provides for a strategic focus in advancing I-Mab's potential of differentiated oncology clinical assets and builds shareholder ... |
| 06.11.2023 | I-Mab Announces Participation at Jefferies and Piper Conferences in November | ROCKVILLE, Md. and SHANGHAI, China, Nov. 6, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the dis... |
| 02.11.2023 | Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Primary Membranous Nephropathy (PMN) | FDA granted Breakthrough Therapy Designation for felzartamab in PMN upon positive clinical data from M-PLACE, a Phase 2 study led by I-Mab partner HI-Bio
I-Mab has full development and commercialization rights of felzartamab in Greater Chin... |
| 01.11.2023 | I-Mab Announces Poster Presentations of 4-1BB Bispecific Antibody Portfolio at SITC 2023 | ROCKVILLE, MD, U.S. and SHANGHAI, China, Nov. 1, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through th... |
| 16.10.2023 | I-Mab Announces Phase 1 Data of Givastomig at ESMO 2023 | ROCKVILLE, Md. and SHANGHAI, China, Oct. 16, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the di... |
| 10.10.2023 | I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB Bispecific Antibody TJ-L14B/ABL503 | - Among 14 efficacy-evaluable patients in the ongoing Phase 1 study, one achieved a complete response, one had partial response and two unconfirmed partial responses; maximum tolerated dose not yet reached
- Patent rights secured for TJ-L14... |
| 05.09.2023 | I-Mab Announces Upcoming Participation at September Conferences | ROCKVILLE, Md. and SHANGHAI, Sept. 5, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the "Company"), is a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discov... |
| 17.08.2023 | I-Mab Provides Mid-Year 2023 Financial Results, Business and Corporate Updates | Significant progress made year-to-date on key clinical assets:
‐ Uliledlimab (CD73 antibody): Encouraging early results were presented at ASCO 2023
‐ Givastomig (Claudin 18.2 x 4-1BB bispecific antibody): Topline Phase 1 data with promising... |
| 08.08.2023 | I-Mab to Report Mid-Year 2023 Financial Results, Business and Corporate Updates on August 17, 2023 | ROCKVILLE, Md. and SHANGHAI, Aug. 8, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of pioneering immunotherapie... |
| 05.07.2023 | I-Mab Announces Publication of Claudin18.2 x 4-1BB Bispecific Antibody Givastomig in JITC | GAITHERSBURG, Md. and SHANGHAI, July 5, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of pioneering immunothera... |
| 22.06.2023 | I-Mab Announces the Appointment of Raj Kannan as CEO | GAITHERSBURG, Md. and SHANGHAI, June 22, 2023 /PRNewswire/ -- I-Mab ("I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of ... |
| 26.05.2023 | I-Mab Announces Encouraging Phase 1b/2 Study Results of Patients with Advanced NSCLC Receiving Uliledlimab and Toripalimab Combination Therapy at ASCO 2023 | - Uliledlimab is a differentiated monoclonal antibody designed to target CD73 and promote stronger activation of patients' immune system against cancer cells.
- In newly diagnosed patients who were not eligible for or declined chemotherapy ... |
| 01.05.2023 | I-MAB Filed 2022 Annual Report on Form 20-F | GAITHERSBURG, Md. and SHANGHAI, May 1, 2023 /PRNewswire/ -- I-Mab ("I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of no... |
| 26.04.2023 | I-Mab Announces Poster Presentation of Proprietary CD73 Antibody Uliledlimab at ASCO 2023 | GAITHERSBURG, Md. and SHANGHAI, April 26, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, tod... |
| 25.04.2023 | I-Mab Announces Positive Outcome in Arbitration Relating to Agreements with Tracon | Award is an important victory for I-Mab and its shareholders on multiple levels, ending the multi-year long dispute
Tribunal completely denied Tracon's groundless damages claim of over $200 million relating to I-Mab's next-generation bi-spe... |
| 24.04.2023 | I-Mab Announces First Patient Dosed in Phase 3 Registrational Study of CD47 Antibody Lemzoparlimab in MDS in China | GAITHERSBURG, Md. and SHANGHAI, April 24, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, tod... |
| 31.03.2023 | I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2022 | Strategic reprioritization of the Company's pipeline to focus on key clinical assets and overall streamlining of corporate structure and workforce, resulting in a significant reduction in the cash burn rate and in significant pipeline achie... |
| 20.03.2023 | I-Mab to Report Full Year 2022 Financial Results and Provide Corporate Update on March 31, 2023 | GAITHERSBURG, Md. and SHANGHAI, China, March 20, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologi... |
| 07.03.2023 | MSCI ESG Updated I-Mab to "A" Rating | GAITHERSBURG, MD. and SHANGHAI, March 7, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, toda... |
| 03.11.2022 | I-Mab Announces Two Poster Presentations of CD47 Antibody Lemzoparlimab at ASH 2022 | GAITHERSBURG, MD. and SHANGHAI, Nov. 3, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today... |
| 13.09.2022 | I-Mab Announces Approval from China CDE to Initiate Phase 3 Registrational Study of Lemzoparlimab in Combination with Azacitidine in Higher-Risk Myelodysplastic Syndrome | GAITHERSBURG, Md. and SHANGHAI, Sept, 13, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, tod... |
| 10.09.2022 | I-Mab Announces Positive Phase 2 Data of Lemzoparlimab in Combination with Azacitidine (AZA) in Patients with Higher Risk Myelodysplastic Syndrome at ESMO 2022 | Lemzoparlimab combined with AZA showed encouraging clinical response in higher-risk MDS patients
For patients received initial dose over 3 months, the ORR is 80.6% and for patients received initial dose over 6 months the ORR is 86.7%, CR ra... |
| 30.08.2022 | I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Six Months Ended June 30, 2022 | Seven key clinical milestones achieved year-to-date, including positive data readouts for lemzoparlimab, uliledlimab, and TJ-CD4B
Lemzoparlimab is on track for Phase 3 study for 1L MDS
Amendment to the global partnership with AbbVie for cer... |
| 23.08.2022 | I-Mab Announces Share Purchase Plans by the Company and the Senior Management | GAITHERSBURG, Md. and SHANGHAI, Aug. 23, 2022 /PRNewswire/ -- I-Mab ("I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of ... |
| 19.08.2022 | I-Mab to Report Business and Corporate Updates and Financial Results for the Six Months Ended June 30, 2022 on August 30, 2022 | - Major updates will focus on global clinical development of core assets, upcoming milestones and financial results
- The Company will update on potential implementation of a comprehensive share purchase program by the Company and current s... |
| 18.07.2022 | I-Mab to Present Phase 2 Clinical Data of CD47 Antibody Lemzoparlimab at ESMO Congress 2022 | GAITHERSBURG, Md. and SHANGHAI, July 18, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, toda... |
| 06.07.2022 | I-Mab to Host 2022 R&D Day | GAITHERSBURG, MD. and SHANGHAI, July 6, 2022 /PRNewswire/ -- I-Mab ("I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of n... |
| 23.06.2022 | I-Mab Receives Top Rankings in Five Categories by Institutional Investor | GAITHERSBURG, Md. and SHANGHAI, June 23, 2022 /PRNewswire/ -- I-Mab ("I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of ... |
| 15.06.2022 | I-Mab Partner MorphoSys Announces New License Agreements for Felzartamab and TJ210 | SHANGHAI and GAITHERSBURG, Md., June 15, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, toda... |
| 31.05.2022 | I-Mab Announces Completion of Patient Enrollment in Phase III Clinical Trial of Eftansomatropin alfa for Treatment of Pediatric Growth Hormone Deficiency | SHANGHAI and GAITHERSBURG, Md., May 31, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today ... |
| 27.05.2022 | I-Mab Reports Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab | - Uliledlimab appears safe and well-tolerated as a monotherapy and a combination therapy with toripalimab with no dose limiting toxicity
- Encouraging efficacy signals were observed in a non-small cell lung cancer (NSCLC) patient cohort
- R... |
| 19.05.2022 | I-Mab to Hold Investor Call to Report Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab | SHANGHAI and GAITHERSBURG, MD., May 19 , 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq" IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, ... |
| 05.05.2022 | I-Mab Provides Updates on Status under Holding Foreign Companies Accountable Act | SHANGHAI and GAITHERSBURG, Md., May 5, 2022 /PRNewswire/ -- I-Mab ("I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of no... |
| 29.04.2022 | I-Mab Announces Appointments of Richard Yeh as Chief Operating Officer and John Hayslip as Chief Medical Officer | - Biotech and Wall Street veteran Mr. Richard Yeh to focus on strategic investor interactions, global alliance management and facilities as COO
- Renowned oncology expert Dr. John Hayslip to further accelerate global clinical development of... |
| 31.03.2022 | I-Mab Announces Voluntary Lock-ups by Key Shareholders and Senior Management for Long-Term Commitment | SHANGHAI and GAITHERSBURG, Md., March 31, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, tod... |
| 29.03.2022 | I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2021 | Financial results demonstrate strong fundamentals
Twenty key clinical milestones achieved year-to-date, including positive data readouts for lemzoparlimab, uliledlimab and felzartamab
Seven business development deals, including a US$315M st... |
| 18.03.2022 | I-Mab to Report Full Year 2021 Financial Results and Provide Corporate Update on March 29, 2022 | SHANGHAI and GAITHERSBURG, MD, March 18, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, toda... |
| 15.03.2022 | I-Mab Provides Updates Regarding Holding Foreign Companies Accountable Act | SHANGHAI and GAITHERSBURG, Md., March 15, 2022 /PRNewswire/ -- I-Mab ( "I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization o... |
| 09.03.2022 | I-Mab Announces Multiple Presentations at the 2022 American Association for Cancer Research (AACR) Annual Meeting | SHANGHAI and GAITHERSBURG, Md., March 9, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, toda... |
| 03.03.2022 | I-Mab Receives FDA Orphan Drug Designation for its Novel Claudin 18.2 x 4-1BB Bispecific Antibody TJ-CD4B for the Treatment of Gastric Cancer | SHANGHAI and GAITHERSBURG, Md., March 3, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, toda... |
| 28.01.2022 | I Mab : Announcement on Unusual Price Movement - Form 6-K | I-Mab's Announcement on Unusual Price Movement
SHANGHAI, China, and GAITHERSBURG, MD. -I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization... |
| 28.01.2022 | I-Mab Announces Partnership Agreement to Localize Manufacturing and Accelerate Commercialization of Innovative Biologics Drugs | SHANGHAI and GAITHERSBURG, Md., Jan. 28, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, anno... |
| 28.01.2022 | I-Mab Announces Partnership Agreement to Localize Manufacturing and Accelerate Commercialization of Innovative Biologics Drugs | SHANGHAI and GAITHERSBURG, Md., Jan. 28, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, anno... |
| 18.01.2022 | I-Mab Announces First Patient Dosed in China Phase 2 Combination Trial of Lemzoparlimab with Toripalimab in Patients with Advanced Solid Tumors | SHANGHAI and GAITHERSBURG, Md., Jan. 18, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today... |
| 18.01.2022 | I-Mab Announces First Patient Dosed in China Phase 2 Combination Trial of Lemzoparlimab with Toripalimab in Patients with Advanced Solid Tumors | SHANGHAI and GAITHERSBURG, Md., Jan. 18, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today... |
| 14.01.2022 | I-Mab Announces Execution of Senior Management Team Share Purchase Plan | The execution demonstrates senior management team's tremendous confidence in the Company's innovative globally competitive pipeline and long-term growth prospects
SHANGHAI and GAITHERSBURG, MD., Jan. 14, 2022 /PRNewswire/ -- I-Mab (the &quo... |
| 12.01.2022 | I-Mab Announces First Patient Dosed in China Phase 2 Clinical Trial of Efineptakin Alfa in Combination with Pembrolizumab in Advanced Solid Tumors | SHANGHAI and GAITHERSBURG, Md., Jan. 12, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, toda... |
| 12.01.2022 | I-Mab Announces First Patient Dosed in China Phase 2 Clinical Trial of Efineptakin Alfa in Combination with Pembrolizumab in Advanced Solid Tumors | SHANGHAI and GAITHERSBURG, Md., Jan. 12, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, toda... |
| 06.01.2022 | I-Mab Announces Senior Management Team Share Purchase Plan | SHANGHAI and GAITHERSBURG, MD., Jan. 6, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today... |
| 31.12.2021 | I-Mab Announces Upcoming Participation at January Conferences | SHANGHAI and GAITHERSBURG, MD., Dec. 31, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, toda... |
| 31.12.2021 | I-Mab Announces Upcoming Participation at January Conferences | SHANGHAI and GAITHERSBURG, MD., Dec. 31, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, toda... |
| 27.12.2021 | I-Mab Announces IND Approval from China NMPA for Phase 2 Clinical Trial of Enoblituzumab in Combination with Pembrolizumab in Solid Tumors | SHANGHAI and GAITHERSBURG, Md., Dec. 27, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, anno... |
| 27.12.2021 | I-Mab Announces IND Approval from China NMPA for Phase 2 Clinical Trial of Enoblituzumab in Combination with Pembrolizumab in Solid Tumors | SHANGHAI and GAITHERSBURG, Md., Dec. 27, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, anno... |
| 20.12.2021 | I-Mab Strengthens Management Team Designed to Accelerate Global Pipeline Development and Transformation Towards Commercialization | - New appointments as part of the Company's strategic development plans to accelerate transformation towards commercialization
- Dr. Andrew Zhu, an internationally renowned oncologist, appointed as President and board director to lead the C... |
| 15.12.2021 | I-Mab Receives IND Approval for Phase 1 Clinical Trial of Bispecific Antibody TJ-CD4B in Solid Tumors in China | SHANGHAI and GAITHERSBURG, Md., Dec. 15, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, toda... |
| 15.12.2021 | I-Mab Receives IND Approval for Phase 1 Clinical Trial of Bispecific Antibody TJ-CD4B in Solid Tumors in China | SHANGHAI and GAITHERSBURG, Md., Dec. 15, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, toda... |
| 09.12.2021 | I-Mab to Hold Investor Call to Present In-depth Clinical Data of Lemzoparlimab in Combination with Rituximab in Non-Hodgkins's Lymphoma | SHANGHAI and GAITHERSBURG, Md., Dec. 9, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today ... |
| 08.12.2021 | I-Mab Announces First Patient Dosed in U.S. Phase 1 Study of Protollin for the Treatment of Alzheimer's Disease | SHANGHAI and GAITHERSBURG, Md., Dec. 8, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today ... |
| 08.12.2021 | I-Mab Announces First Patient Dosed in U.S. Phase 1 Study of Protollin for the Treatment of Alzheimer's Disease | SHANGHAI and GAITHERSBURG, Md., Dec. 8, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today ... |
| 07.12.2021 | I-Mab to Pursue Dual Listing Plan on The Main Board of The Stock Exchange of Hong Kong Limited | SHANGHAI and GAITHERSBURG, Md., Dec. 7, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today ... |
| 06.12.2021 | I Mab : Announces First Two Patients Dosed in U.S. Phase 2 Combination Trial of Uliledlimab with Atezolizumab in Patients with Selected Advanced Solid Tumors - Form 6-K | I-Mab Announces First Two Patients Dosed in U.S. Phase 2 Combination Trial of Uliledlimab with Atezolizumab in Patients with Selected Advanced Solid Tumors
SHANGHAI, CHINA, and GAITHERSBURG, MD. December 3, 2021- I-Mab (the "Company&qu... |
| 03.12.2021 | I-Mab Announces First Two Patients Dosed in U.S. Phase 2 Combination Trial of Uliledlimab with Atezolizumab in Patients with Selected Advanced Solid Tumors | SHANGHAI and GAITHERSBURG, Md., Dec. 3, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today ... |
| 03.12.2021 | I-Mab Announces First Two Patients Dosed in U.S. Phase 2 Combination Trial of Uliledlimab with Atezolizumab in Patients with Selected Advanced Solid Tumors | SHANGHAI and GAITHERSBURG, Md., Dec. 3, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today ... |
| 10.11.2021 | I-Mab and Jumpcan Announce Strategic Commercial Partnership on Eftansomatropin Alfa | The partnership brings together the strengths of an innovative global biotech and a domestic leading pharmaceutical company specialized in and committed to pediatric medicines to accelerate the commercialization of eftansomatropin alfa
Jump... |
| 09.11.2021 | I-Mab and ABL Bio Report Preclinical Data of 4-1BB-targeting Bispecific Antibodies at 2021 SITC | Preclinical data of TJ-CD4B/ABL111 and TJ-L14B/ABL503 demonstrate targeted safety profile and enhanced anti-tumor activity
Both studies are undergoing phase 1 clinical trials in the United States
SHANGHAI and GAITHERSBURG, Md. and SEONGNAM,... |
| 08.11.2021 | I-Mab and Roche Diagnostics Announce Strategic Collaboration to Co-Develop Companion Diagnostics Solutions for I-Mab's Innovative Pipeline at the 4th CIIE | SHANGHAI and GAITHERSBURG, Md., Nov. 8, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today ... |
| 04.11.2021 | I-Mab to Present Clinical Data of Lemzoparlimab in Combination with Rituximab in Non-Hodgkins's Lymphoma at ASH 2021 | Lemzoparlimab is a differentiated CD47 monoclonal antibody discovered by I-Mab and being developed in collaboration with AbbVie
Initial clinical results of lemzoparlimab in combination with rituximab in NHL will be presented at the ASH 2021... |
| 03.11.2021 | I-Mab Announces Upcoming Participation at November Conferences | SHANGHAI and GAITHERSBURG, Md., Nov. 3, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today... |
| 03.11.2021 | I-Mab Announces Upcoming Participation at November Conferences | SHANGHAI and GAITHERSBURG, Md., Nov. 3, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today... |
| 02.11.2021 | I-Mab Strengthens Senior Executive Team with New Chief Financial Officer and Chief Strategy Officer Appointments - Form 6-K | I-Mab Strengthens Senior Executive Team with New Chief Financial Officer and Chief Strategy
Officer Appointments
- Industry veteran John Long appointed as CFO to lead I-Mab's global corporate finance and capital market activities
- Jielun Z... |
| 01.11.2021 | I-Mab Strengthens Senior Executive Team with New Chief Financial Officer and Chief Strategy Officer Appointments | SHANGHAI and GAITHERSBURG, Md., Nov. 1, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today... |
| 01.11.2021 | I-Mab Strengthens Senior Executive Team with New Chief Financial Officer and Chief Strategy Officer Appointments | - Industry veteran John Long appointed as CFO to lead I-Mab's global corporate finance and capital market activities
- Jielun Zhu named as CSO to focus on corporate strategy, strategic partnerships and transactions, and corporate ventures
-... |
| 26.10.2021 | I-Mab Announces Strategic Partnership with Sinopharm in Preparation for Launch of its Innovative Assets in China | I-Mab strategic partnership with Sinopharm will covers all aspects of the go-to-market process, including authorization of more than 300 Sinopharm's subsidiaries as distributors across China.
I-Mab is on track to submit BLA for third line m... |
| 26.10.2021 | I-Mab Announces Strategic Partnership with Sinopharm in Preparation for Launch of its Innovative Assets in China | I-Mab strategic partnership with Sinopharm will covers all aspects of the go-to-market process, including authorization of more than 300 Sinopharm's subsidiaries as distributors across China.
I-Mab is on track to submit BLA for third line m... |
| 22.10.2021 | I-Mab : Expands U.S. Footprint with New R&D Site in San Diego | - I-Mab will strengthen its global R&D presence, with a new world-class R&D and operational site, located in the heart of the rapidly growing San Diego biotech hub
- The new site will complement I-Mab's Global Clinical Development s... |
| 22.10.2021 | I-Mab Expands U.S. Footprint with New R&D Site in San Diego | - I-Mab will strengthen its global R&D presence, with a new world-class R&D and operational site, located in the heart of the rapidly growing San Diego biotech hub
- The new site will complement I-Mab's Global Clinical Development s... |
| 19.10.2021 | I Mab : Announces IND Approval for Phase 2 Clinical Trial of Efineptakin Alfa in Combination with PD-1 Therapy in China - Form 6-K | I-Mab Announces IND Approval for Phase 2 Clinical Trial of Efineptakin Alfa in Combination with PD-1 Therapy in China
SHANGHAI, China and GAITHERSBURG, MD. October 18, 2021 -I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage b... |
| 18.10.2021 | I-Mab Announces IND Approval for Phase 2 Clinical Trial of Efineptakin Alfa in Combination with PD-1 Therapy in China | SHANGHAI and GAITHERSBURG, Md., Oct. 18, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, toda... |
| 18.10.2021 | I-Mab : Announces IND Approval for Phase 2 Clinical Trial of Efineptakin Alfa in Combination with PD-1 Therapy in China | SHANGHAI and GAITHERSBURG, Md., Oct. 18, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, toda... |
| 13.10.2021 | I-Mab Advances Late-stage Development of Its Differentiated CD38 Antibody Felzartamab (TJ202) in China | Completed patient enrollment in phase 3 registrational trial of felzartamab in combination with lenalidomide for second-line treatment of multiple myeloma (MM)
Felzartamab for MM third-line treatment is on track for BLA submission in Q4 202... |
| 01.10.2021 | I-Mab : Announces Upcoming Participation at October Conferences | SHANGHAI and GAITHERSBURG, Md., Oct. 1, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today ... |
